164 related articles for article (PubMed ID: 37879723)
1. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.
Mitchell AP; Dusetzina SB; Mishra Meza A; Trivedi NU; Bach PB; Winn AN
BMJ; 2023 Oct; 383():e075512. PubMed ID: 37879723
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.
Mitchell AP; Winn AN; Lund JL; Dusetzina SB
Oncologist; 2019 May; 24(5):632-639. PubMed ID: 30728276
[TBL] [Abstract][Full Text] [Related]
3. Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.
Mitchell AP; Mishra Meza A; Trivedi NU; Bach PB; Gönen M
Oncologist; 2022 Oct; 27(10):857-863. PubMed ID: 35946837
[TBL] [Abstract][Full Text] [Related]
4. Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.
Rahman MW; Trivedi NU; Bach PB; Mitchell AP
J Natl Compr Canc Netw; 2021 Dec; 20(13):1-9. PubMed ID: 34965511
[TBL] [Abstract][Full Text] [Related]
5. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia.
Wood SF; Podrasky J; McMonagle MA; Raveendran J; Bysshe T; Hogenmiller A; Fugh-Berman A
PLoS One; 2017; 12(10):e0186060. PubMed ID: 29069085
[TBL] [Abstract][Full Text] [Related]
6. The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.
Bandari J; Turner RM; Jacobs BL; Canes D; Moinzadeh A; Davies BJ
Urol Pract; 2017 Jan; 4(1):14-20. PubMed ID: 28149927
[TBL] [Abstract][Full Text] [Related]
7. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
9. Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies.
Manz CR; Tramontano AC; Uno H; Parikh RB; Bekelman JE; Schrag D
JAMA Netw Open; 2022 Sep; 5(9):e2234161. PubMed ID: 36173630
[TBL] [Abstract][Full Text] [Related]
10. Trends in Industry Payments to Medical Oncologists in the United States Since the Inception of the Open Payments Program, 2014 to 2019.
Tarras ES; Marshall DC; Rosenzweig K; Korenstein D; Chimonas S
JAMA Oncol; 2021 Mar; 7(3):440-444. PubMed ID: 33377904
[TBL] [Abstract][Full Text] [Related]
11. The Role of Physician Professional Networks in Physicians' Receipt of Pharmaceutical and Medical Device Industries' Payments.
Winn AN; Mitchell AP; Fergestrom N; Neuner JM; Trogdon JG
J Gen Intern Med; 2021 Jul; 36(7):1858-1866. PubMed ID: 33904046
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US.
Nguyen AM; Anderson KE; Anderson G; Johnson TV
JAMA Ophthalmol; 2022 Sep; 140(9):855-862. PubMed ID: 35900736
[TBL] [Abstract][Full Text] [Related]
14. Association between physician characteristics and payments from industry in 2015-2017: observational study.
Inoue K; Blumenthal DM; Elashoff D; Tsugawa Y
BMJ Open; 2019 Sep; 9(9):e031010. PubMed ID: 31542759
[TBL] [Abstract][Full Text] [Related]
15. Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.
Marshall DC; Moy B; Jackson ME; Mackey TK; Hattangadi-Gluth JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27389914
[TBL] [Abstract][Full Text] [Related]
16. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
17. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Affordable Care Act's Physician Payments Sunshine Act on branded statin prescribing.
Li J; Wu B; Flory J; Jung J
Health Serv Res; 2022 Oct; 57(5):1145-1153. PubMed ID: 35808991
[TBL] [Abstract][Full Text] [Related]
19. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
20. Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries.
Mahr MA; Hodge DO; Erie JC
Ophthalmol Retina; 2017; 1(1):19-24. PubMed ID: 31047391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
